| Study Period | 2019 - 2030 |
| 2024 Market Size | USD 19,228.9 Million |
| 2025 Market Size | USD 23,022.7 Million |
| 2030 Forecast | USD 61,220.9 Million |
| Growth Rate(CAGR) | 21.6% |
| Largest Region | North America |
| Fastest Growing Region | Asia-Pacific |
| Nature of the Market | Fragmented |
| Largest Application Category | Medical |
|
Explore the market potential with our data-driven report
The global synthetic biology market size stands at USD 19,228.9 million in 2024, which is expected to reach USD 61,220.9 million by 2030, advancing at a CAGR of 21.6% during 2025–2030. This will prominently be due to the declining costs of DNA sequencing and the availability of efficient and accurate next-genome sequencing systems at lower costs. Further, the increase in several initiatives in synthetic biology research coupled with high R&D funding from the governments as well as private bodies is the other factor that will boost the market size in the forecast period.
The increasing adoption of the NGS technology by pharmaceutical & biopharmaceutical firms in several countries is positively impacting the market outlook. The rising prevalence of chronic diseases, including diabetes and cancer, and autoimmune diseases have resulted in an increased need for innovative treatments. Attributed to this, key players are focusing on supplying superior quality instruments to pharmaceutical organizations and research centers, which are engaged in the development of therapies for genetic diseases. The different biological tools have further helped biopharmaceutical and pharmaceutical organizations design therapies as per the nature of the disease.
The use of nanopore sequencing technology for developing NGS platforms is one of the key trends observed in the market. These platforms provide high throughput sequencing to researchers and scientists along with reduced cost and high speed. Traditional sequencing methods, including the Sanger method, are expensive, sluggish, and require a large amount of template DNA, and biological platforms have assisted in disabling these limitations with more precise results.
The oligonucleotides & synthetic DNA category accounts for the largest revenue share in 2024, of around 45%. This is mainly ascribed to the high demand for synthetic genes, synthetic RNA, and synthetic DNA for numerous applications in forensic sciences and genetic testing. Synthetically manufactured oligonucleotides act as a molecular tool in the construction of large cell populations having multiple genotypes, therefore aiding in genetic engineering, which is currently high in demand. Apart from research, oligonucleotides have widespread use in the diagnosis of disease and in therapeutic areas.
The outbreak of the COVID-19 pandemic has intensified the use of PCR for the detection and analysis of specific gene sequences, which mainly utilize oligonucleotides as a primer, thereby acting as a catalyst for the market growth. In the biopharmaceutical industry, oligonucleotides are significantly used for allele-specific assays, aptamer designing, and dsDNA binding purposes. Moreover, the increasing adoption of DNA computing, CRISPR gene editing, and mutagenesis experiments are expected to offer lucrative opportunities in the market in the coming years.
In addition, prominent players have been actively involved in the launch of innovative and personalized oligonucleotides & synthetic DNA tools, which offer inexpensive genomic experiments. For instance, OligoMix launched by LC Sciences LLC is 20 times more efficient than conventional oligos, and costs around 0.8 cents per base.
The enzymes category is expected to experience the highest CAGR during the forecast period in the market. This will be on account of the high capability of enzymes in delivering lengthier genes in a very less turnaround time. The alteration of enzymes for their use as synthetic biology tools aids in posttranslational modification and genetic modification, which is the other factor boosting the revenue share of this category. Amylase, xylanase, lipase, and protease are some of the major enzymes being used in pharmaceutical companies for genetic engineering purposes.
The tools analyzed in the report are listed below:
The medical category dominates the market, attributed to the surging use of synthetic biology for the highly sensitive, non-invasive, and real-time detection of numerous infectious agents and cancer cells. The adoption of rational engineering technologies by researchers for the designing of novel bio-sensing systems comprising sensors, reporters, and processors also enhances the market size. In addition, the rise in neurological disorders such as multiple sclerosis and the efforts taken by key players to develop novel therapies with the aid of synthetic biology are also leading to high demand for synthetic biology in healthcare applications.
In recent times, there has been a breakthrough in the field of medicine with the aid of systematic and rational biological designs in the development of diagnostic methods. Synthetic biology-based diagnostics are dynamic and highly specific for the diagnosis as well as monitoring of metabolic parameters, tumor cells, infectious pathogens, and toxin exposure. The adoption of synthetic biology has revolutionized the healthcare sector in several areas such as drug discovery, monitoring of therapeutics, synthesis of APIs, development of alternate therapies, and vaccine development, thereby leading to high market revenue.
Pharmaceutical applications of synthetic biology are expected to experience the highest CAGR, of around 22%, during 2024–2030 in the market. This can be mainly due to the active involvement of pharma & biotech firms in the development of novel therapeutics for innumerable chronic diseases like cancer, diabetes, and cirrhosis, with the use of synthetic biology. For instance, Merck & Co. Inc. made use of synthetic biology techniques for the development of Januvia (sitagliptin), which is a type 2 diabetes medicine.
The following applications have been studied:
Sequencing is the largest category in the market. This is attributed to the extensive usage of next-generation sequencing (NGS) to determine the exact nucleotide sequence. This is often the first step in the multi-omics approach and helps drive further studies on genes, their expression, modification, and potential for disfunction or mutation. Sequencing the DNA is becoming increasingly vital in diagnostics, forensics, biomarker & cancer research, precision medicine, and reproductive health.
Genome engineering is the fastest-growing category on account of the rising application of this technology across industries. The CRISPR technology is extensively used to find treatments for diseases with a prominent genetic cause, such as cancer, hyperlipidemia, and neurodegenerative diseases. Other key applications of genome engineering are industrial green chemicals, genetically modified crops, and biofuels.
These technologies are part of the research scope:
Drive strategic growth with comprehensive market analysis
North America leads the synthetic biology market in 2024 primarily due to the rising government projects on countless novel biological compound synthesis, highly developed healthcare infrastructure, the presence of a large number of research laboratories performing their studies on innumerable rare and genetic-based diseases, advancements in genome sequencing, and a large number of synthetic biology patents. In addition, the presence of a large number of prominent players and the rising number of collaborations and product launches by these players in the region are other factors burgeoning the market outlook.
Furthermore, huge investments being made in genomics by both private and public organizations, including in research projects, are fueling the expansion of the market. The U.S. is perceiving huge investments in this field, owing to initiatives done by the NHGRI. These programs aim to recognize various barriers limiting the adoption of genomics in clinical care and formulate the best practices and solutions for achieving their widespread incorporation in the country.
The APAC market is set to register the highest CAGR in the forecast period, due to the rising partnerships and funding by major players and the snowballing collaborations in the field of synthetic biology in the region. The surging number of research activities being carried out in the domain of genomics in China, Japan, and India and the soaring investments being made by public and private organizations are the key factors propelling the advancement of the regional market.
India is one of the largest pharmaceutical hubs in APAC and demands advanced biomanufacturing technologies in various industrial segments. Many global players, such as Thermo Fischer Scientific Inc., are doing partnerships with companies in India to set up their infrastructure and capture a larger market share, which is driving the market growth.
Globally, Europe is the second-highest revenue-generating market, owing to the non-profit establishments that have combined their financial resources to boost the development of RNA-based treatments, in response to the mounting demand for RNA therapies to address unmet medical needs. Also, the increasing need for personalized medicines, for better clinical results and pharmaceutical safety, has assisted the market expansion in the region.
Below is the regional breakdown of the market:
Want a report tailored exactly to your business need?
Request CustomizationLeading companies across industries trust us to deliver data-driven insights and innovative solutions for their most critical decisions. From data-driven strategies to actionable insights, we empower the decision-makers who shape industries and define the future. From Fortune 500 companies to innovative startups, we are proud to partner with organisations that drive progress in their industries.
Working with P&S Intelligence and their team was an absolute pleasure – their awareness of timelines and commitment to value greatly contributed to our project's success. Eagerly anticipating future collaborations.
McKinsey & Company
India
Our insights into the minutest levels of the markets, including the latest trends and competitive landscape, give you all the answers you need to take your business to new heights
We take a cautious approach to protecting your personal and confidential information. Trust is the strongest bond that connects us and our clients, and trust we build by complying with all international and domestic data protection and privacy laws
Customize the Report to Align with Your Business Objectives
Request the Free Sample Pages